Bausch + Lomb Corporation (BLCO)
NYSE:BLCO
Want to see BLCO full AI Analyst Report?
BLCO Stock Chart & Stats
$16.82
$0.21(1.15%)
At close: 4:00 PM EST
$16.82
$0.21(1.15%)
Day’s Range― - ―
52-Week Range$11.44 - $18.92
Previous CloseN/A
Volume107.99K
Average Volume (3M)405.48K
Market Cap
$5.34B
Enterprise Value$5.35B
Total Cash (Recent Filing)$268.00M
Total Debt (Recent Filing)$39.00M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Aug 05, 2026EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding356,536,350
10 Day Avg. Volume391,487
30 Day Avg. Volume405,477
Financial Highlights & Ratios
PEG Ratio-1.26
Price to Book (P/B)0.94
Price to Sales (P/S)1.18
P/FCF Ratio-91.56
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue1.03
Enterprise Value/Gross Profit1.84
Enterprise Value/Ebitda7.39
Forecast
1Y Price Target
$18.38Price Target Upside9.24% Upside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)0.8
Revenue Forecast (FY)$5.47B
Bulls Say, Bears Say
Bulls Say
Margin Expansion And Operating LeverageSubstantial adjusted EBITDA and gross-margin improvement reflect durable operating leverage from higher-margin Pharma and premium products. Sustained margin expansion supports reinvestment in R&D and commercial buildouts, improving profitability resilience beyond transitory items.
Diversified, Growing Revenue BaseConsistent top-line growth across contact lenses, lens care, pharmaceuticals and surgical products indicates a diversified revenue mix. Recurring consumables and prescription products provide stable demand, while pharmaceutical momentum and premium surgical adoption broaden long-term growth avenues.
Improved Leverage And Balance-sheet StrengthDramatically lower reported leverage and a solid equity base increase financial flexibility for capex, R&D, or strategic M&A. A stronger balance sheet reduces refinancing risk and provides capacity to support multi-year commercialization and pipeline investments.
Bears Say
Negative Net MarginsOngoing negative net margins mean GAAP profitability has not been reached despite operating improvements. Persistent accounting losses limit retained earnings accumulation, constrain capital allocation flexibility, and may require continued operational gains to translate adjusted EBITDA into sustainable net income.
Weak Free Cash Flow ConversionThin or inconsistent free cash flow reduces internal funding available for R&D, capex, or balance-sheet repair. Even with improving OCF, near-breakeven FCF means the company may remain dependent on careful cash management or external financing to sustain multi-year investments and debt targets.
Surgical And Regional Execution RisksExecution headwinds in surgical and certain international markets indicate dependency on field sales effectiveness and procedure volumes. Reimbursement pressures and regional volatility can persistently compress surgical sales and equipment placements, tempering durable growth in the premium surgical franchise.
Bausch + Lomb Corporation News
BLCO FAQ
What was Bausch + Lomb Corporation’s price range in the past 12 months?
Bausch + Lomb Corporation lowest stock price was $11.44 and its highest was $18.91 in the past 12 months.
What is Bausch + Lomb Corporation’s market cap?
Bausch + Lomb Corporation’s market cap is $5.34B.
When is Bausch + Lomb Corporation’s upcoming earnings report date?
Bausch + Lomb Corporation’s upcoming earnings report date is Aug 05, 2026 which is in 62 days.
How were Bausch + Lomb Corporation’s earnings last quarter?
Bausch + Lomb Corporation released its earnings results on Apr 29, 2026. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.051 by $0.029.
Is Bausch + Lomb Corporation overvalued?
According to Wall Street analysts Bausch + Lomb Corporation’s price is currently Undervalued.
Does Bausch + Lomb Corporation pay dividends?
Bausch + Lomb Corporation does not currently pay dividends.
What is Bausch + Lomb Corporation’s EPS estimate?
Bausch + Lomb Corporation’s EPS estimate is 0.15.
How many shares outstanding does Bausch + Lomb Corporation have?
Bausch + Lomb Corporation has 356,536,350 shares outstanding.
What happened to Bausch + Lomb Corporation’s price movement after its last earnings report?
Bausch + Lomb Corporation reported an EPS of $0.08 in its last earnings report, beating expectations of $0.051. Following the earnings report the stock price went down -2.417%.
Which hedge fund is a major shareholder of Bausch + Lomb Corporation?
Currently, no hedge funds are holding shares in BLCO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bausch + Lomb Corporation Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$18.38 (9.24% Upside)
$18.38 (9.24% Upside)
Blogger Sentiment
Bullish
BLCO Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 594.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $650.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.00%
12-Months-Change
Fundamentals
Return on Equity
-3.41%
Trailing 12-Months
Asset Growth
2.62%
Trailing 12-Months
Company Description
Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
BLCO Company Deck
BLCO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial progress on execution: consistent revenue growth, large adjusted EBITDA and margin expansion, strong Pharma and premium product momentum, active pipeline and elevated R&D investment — all supported by a modest guidance raise. Lowlights were mostly transitional or seasonal (Surgical field-force rebuild, weather-related disruptions, regional softness, prescription seasonality, and cash/capex timing). Overall, the positives—material margin improvement, strong product-level growth (notably Miebo, Xiidra, Daily SiHy, premium IOLs), and upgraded guidance—outweigh the temporary challenges.View all BLCO earnings summariesBLCO Stock 12 Month Forecast
Average Price Target
$18.38
▲(9.24% Upside)
Technical Analysis
Ownership Overview
0.74% Insiders
0.43% Mutual Funds
6.32% Other Institutional Investors
92.16% Public Companies and
Individual Investors